KAT8 is a lysine acetyltransferase primarily catalyzing the acetylation of Lys16 of histone H4 (H4K16). KAT8 dysregulation is linked to the development and metastatization of many cancer types, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML). Few KAT8 inhibitors have been reported so far, none of which displaying selective activity. Based on the KAT3B/KDAC inhibitor C646, we developed a series of N-phenyl-5-pyrazolone derivatives and identified compounds 19 and 34 as low-micromolar KAT8 inhibitors selective over a panel of KATs and KDACs. Western blot, immunofluorescence, and CETSA experiments demonstrated that both inhibitors selectively target KAT8 in cells. Moreover, 19 and 34 exhibited mid-micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, without impacting the viability of nontransformed cells. Overall, these compounds are valuable tools for elucidating KAT8 biology, and their simple structures make them promising candidates for future optimization studies.
First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8 / Fiorentino, F.; Sementilli, S.; Menna, M.; Turrisi, F.; Tomassi, S.; Pellegrini, F. R.; Iuzzolino, A.; D'Acunzo, F.; Feoli, A.; Wapenaar, H.; Taraglio, S.; Fraschetti, C.; Del Bufalo, D.; Sbardella, G.; Dekker, F. J.; Paiardini, A.; Trisciuoglio, D.; Mai, A.; Rotili, D.. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 66:10(2023), pp. 6591-6616. [10.1021/acs.jmedchem.2c01937]
First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8
Tomassi S.Membro del Collaboration Group
;Pellegrini F. R.;Sbardella G.;
2023
Abstract
KAT8 is a lysine acetyltransferase primarily catalyzing the acetylation of Lys16 of histone H4 (H4K16). KAT8 dysregulation is linked to the development and metastatization of many cancer types, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML). Few KAT8 inhibitors have been reported so far, none of which displaying selective activity. Based on the KAT3B/KDAC inhibitor C646, we developed a series of N-phenyl-5-pyrazolone derivatives and identified compounds 19 and 34 as low-micromolar KAT8 inhibitors selective over a panel of KATs and KDACs. Western blot, immunofluorescence, and CETSA experiments demonstrated that both inhibitors selectively target KAT8 in cells. Moreover, 19 and 34 exhibited mid-micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, without impacting the viability of nontransformed cells. Overall, these compounds are valuable tools for elucidating KAT8 biology, and their simple structures make them promising candidates for future optimization studies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
